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A B S T R A C T
Background: Breast cancer (BC) is a major public health concern with over 2 million new cases diagnosed and
over 600,000 deaths in 2018 in women worldwide. When distant metastases are present at diagnosis, the 5-year
survival rate is only 26%. Recent studies have suggested that persistent organic pollutants (POPs) that accu-
mulate in adipose tissue (AT) can influence tumor phenotype and stimulate cellular processes important for
metastasis such as invasion. We, therefore, tested the hypothesis that POP exposure is associated with BC me-
tastasis.
Methods: We conducted an exploratory case-control study in which the concentrations of 49 POPs were mea-
sured in both AT and serum samples from BC patients, with or without lymph node metastasis, who underwent
partial or total mastectomies, lymph node biopsies and sampling of the adipocytic tumor microenvironment.
Adjusted, unconditional logistic models were used to study the associations between the POP concentrations and
the risk of metastasis and other hallmarks of cancer aggressiveness.
Results: 2.3.7.8-TCDD concentrations in AT are positively associated with the risk of metastasis in 43 patients
who have BMIs equal or higher than 25 kg/m2 (odds ratio: 4.48 (1.32–20.71)). Furthermore, the concentrations
of 2.3.7.8-TCDD and two coplanar PCBs (77&169) in AT also were positively associated with the risk of lymph
node metastasis and the tumor size.
Conclusion: Our study suggests that 2.3.7.8-TCDD and some PCBs contribute to the development of tumor
metastasis and other hallmarks of cancer aggressiveness. While these results should be considered with caution,
this is the first study to identify such potential risk factors. Larger longitudinal studies are necessary to confirm
our results.
Clinical Trial Protocol Record: 2013-A00663-42.
1. Introduction
Breast cancer (BC) is a major health concern with over 2 million
new cases diagnosed in 2018 in women worldwide (Bray et al., 2018). If
the cancer is located only in the breast, the 5-year survival rate is 99%
but this rate decreases if there is spread to lymph nodes (85%). How-
ever, if distant metastases are present upon diagnosis the survival rate
drops dramatically (26%) (Howlader et al., 1975; Siegel et al., 2017).
The exposure to environmental pollutants has been proposed, re-
cently, as a risk factor for BC (Lauby-Secretan et al., 2013; Leng et al.,
2016; Rodgers et al., 2018; Zhang et al., 2015). Polychlorinated bi-
phenyls (PCBs) and organochlorine pesticides (OCPs) have been iden-
tified as endocrine-disrupting-chemicals (EDC) and/or as carcinogens.
Some of these compounds are persistent organic pollutants (POPs) since
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their hydrophobicity favors their bioaccumulation throughout the food
chain. Overall, the scientific evidence concerning the associations be-
tween EDC and BC risk in humans has been inconclusive (Ochieng
et al., 2015).
To date, researchers have been interested mainly in the link be-
tween BC initiation and EDC. Only a few recent studies have explored
the associations with late stages of cancer, such as metastasis, which is
the main cause of BC mortality. We have shown that TCDD (2,3,7,8-
Tetrachlorodibenzo-p-dioxin) triggers invasive processes using human
tumor cell lines as model systems (Bui et al., 2009; Diry et al., 2006;
Pierre et al., 2014; Tomkiewicz et al., 2013). TCDD is best known for its
induction of the AhR signalling pathway. AhR is responsive to many
POPs (including PCBs) and aromatic hydrocarbons. Two studies have
demonstrated an association between smoking and pulmonary metas-
tasis among women with BC (Murin and Inciardi, 2001; Scanlon et al.,
1995). Among POPs, TCDD is suspected to act as an endocrine disruptor
similarly to organochlorine compounds (OCs). Several studies which
focused on the impact of POPs and non-POPs on the initiation of breast
cancer did not demonstrate a relationship between xenobiotics ex-
posure and the incidence of BC (Høyer et al., 2000; Muscat et al., 2003;
Parada et al., 2016a, 2016b; Roswall et al., 2018). However, p,p′-DDE
was found to be associated with a dose-related increased relative risk of
both lymph-node involvement and large tumors which suggests a po-
tential relationship with tumor aggressiveness (Dairkee et al., 2008;
Demers et al., 2000; Parada et al., 2019). Further, a very recent study
found that higher levels of p,p′-DDE and DDT in the blood were asso-
ciated with worse overall survival (Parada et al., 2019). Also, it has
been shown that breast cancer cells exposed to Bisphenol A, another
endocrine disruptor (non-POP), exhibit a gene expression profile of
tumor aggressiveness which is associated with poor clinical outcomes
for breast cancer patients (Dairkee et al., 2008). Finally, several POPs
trigger metastatis formation in mice (Castillo-Sanchez et al., 2013; Guo
et al., 2015; Liu et al., 2010; Ochieng et al., 2015; Pierozan et al., 2018;
Pontillo et al., 2013; Seelbach et al., 2010; Zhang et al., 2016).
Since no observational studies have been conducted to evaluate the
link between EDC and BC metastasis, we conducted an exploratory,
hospital-based case-control study to analyze the concentrations of 49
POPs in samples of adipose tissue (AT) and serum from breast cancer
patients with and without lymph node metastasis. We also analyzed the
effect of obesity since this factor is associated with larger tumors, po-
sitive lymph node status and overall survival (Picon-Ruiz et al., 2017).
2. Material and methods
2.1. Study design
A monocentric cohort study (Clinical Trial Protocol Record 2013-
A00663-42) was conducted in the Department of gynecological-onco-
logical surgery of the Georges-Pompidou European Hospital (Paris,
France) from 12/2013 to 11/2017. Participation in the study was
proposed to each female newly diagnosed for BC and operated in the
department, aged 18 years or more, who possessed a uni- or multifocal
lesion with the principal lesion being> 1 cm in size or palpable. All
patients (10% of total BC population) gave informed consent to parti-
cipate in the study, which was approved by the ‘Comité de Protection
des Personnes’ in 2013 [French equivalent of an Institutional Review
Board (IRB)]. Patients unable to give informed consent were not in-
cluded. The reasons for not participating in the study were: 1) Non-
palpable lesions. The lesion had to be palpable so that peritumoral
adipose tissue could be easily collected; 2) Patients who have an ex-
cessive number of solicitations from many studies in the department
with a large number of questionnaires; 3) Men were removed from the
study for reasons of homogeneity. At enrollment, the participants
completed an assisted lifestyle questionnaire and provided a blood
sample to assess POP concentrations before any treatment was initiated.
Patients underwent partial or total mastectomy. Lymph node biopsy
and axillary lymph node removal (depending upon the lymph node
biopsy results) were performed according to the American Society of
Clinical Oncology (ASCO) guidelines. During the surgery, an adipose
tissue sample (1–3 g) was obtained at a distance of 1 cm from the
palpable tumor for the measurement of POPs. The cancer tissue re-
moved during the surgery was sent to the pathology laboratory for
clinical analyses. Nodal status was determined for each patient. Patients
were classified into 2 groups and participants with lymph node in-
volvement were placed in the metastatic group (classification was
performed without any information regarding the POP measurement).
All the patients' data were anonymized and recorded on a computerized
database (Fig. 1).
2.2. Chemical analysis
The methodologies for the isolation, detection and quantification of
the targeted POPs, including dioxins (PCDD/F), polychlorobiphenyls
(PCB), polybromodiphenylethers (PBDE), polybromobiphenyls (PBB)
and hexabromocyclododecane (HBCD), have been described (Antignac
et al., 2006, 2009; Bichon et al., 2015; Cariou et al., 2005; Costera et al.,
2006; Ploteau et al., 2016). The complete list of chemicals (IUPAC) can
be found in Table S1. Briefly, samples were first submitted to a high
pressure and temperature extraction (ASE Dionex, Sunnyvale, CA, USA)
(fat) or a liquid/liquid extraction with pentane (serum). The resulting
extracts were weighed to measure fat content (gravimetric method for
fat, enzymatic determination for serum) and reconstituted in hexane for
further sample clean up. PCDD/F, PCB, PBDE and PBB measurements
were performed by gas chromatography (Agilent 7890A) coupled to
high-resolution mass spectrometry (GC-HRMS) on double sector in-
struments (JEOL MS 700D and 800D) after electron impact ionization
(70 eV; 10% valley) and in the single ion monitoring (SIM) acquisition
mode. The three HBCD isomers (alpha, beta and gamma) were quan-
tified using liquid chromatography coupled to tandem mass spectro-
metry (LC-MS/MS) on a triple quadrupole instrument (Agilent 6410)
using electrospray ionization and selective reaction monitoring as the
acquisition technique. All the analyses were conducted in an ISO
17025:2005 accredited laboratory. The lipid content for serum samples
was determined with enzymatic kits (Biolabo, Maizy, France) which
allowed determination of the concentrations of phospholipids (PHO),
triacylglycerides (TAG), total cholesterol (t.CHO) and free cholesterol
(f.CHO). Total serum lipids (TSL) were estimated using the following
formula (Akins et al., 1989): TSL= 1.677 * (t.CHO− f.CHO)
+ (f.CHO+TAG+PHO).
2.3. Statistical analysis
Demographic characteristics were summarized using the median
and interquartile range, for continuous variables, and the frequency and
percentage, for categorical variables. The statistical comparison of de-
mographic characteristics between groups (i.e. metastatic versus non-
metastatic) was performed using the Mann-Whitney-Wilcoxon Test and
Fisher's exact test, for the numerical and the categorical variables, re-
spectively. The associations calculated with Spearman's correlation
coefficients were plotted in heatmaps. The distributions of POPs be-
tween groups were summarized by medians and interquartile ranges
and compared statistically using Mann-Whitney-Wilcoxon Tests. Those
chemicals with detection rates below 75% were excluded from the
statistical analysis and for the analytes whose detection rates were
between 75 and 100%, the non-detected values were replaced by the
limits of detection (Antweiler 2015).
Crude odds ratios (ORs), adjusted ORs (aORs) and corresponding
95% confidence intervals (CI) were calculated for each chemical
(transformed to the natural logarithm) using unconditional logistic re-
gression considering the non-metastatic cancer group as referent. Three
adjusted models were considered to account for predefined variables
known as factors which affect the internal levels of POPs and the risk of
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cancer. The confounding variables in the first adjusted model were the
age, smoking and menopause. In the second adjusted model, we further
included the body mass index (BMI) to evaluate the effect of adiposity
as a potential confounder. In the third adjusted model, the familial
history of BC also was included in the final model. Due to the small
influence of confounding variables in the risk estimates, we only re-
ported the results of the crude and fully adjusted models in the main
manuscript.
We further explored whether the concentrations of POPs were as-
sociated with the number of lymph nodes affected, classified according
to the international TNM classification of breast cancer (N1≤3 nodes,
N2= 4–9 nodes, N3≥10 positive nodes). The groups N2 and N3 were
combined for the statistical analysis due to the low number of in-
dividuals in each group. This classification aims to better anticipate the
aggressiveness of the tumor and its spreading potential. Tumor size was
evaluated as an independent outcome of cancer aggressiveness by di-
chotomizing the cases, according to the median of the distribution of
tumor sizes, into a group of small tumor size and another with large size
(cut off=2 cm). The concentrations of POPs were compared between
the two groups with adjustments to POPs concentrations for BMI, age
and familial breast cancer history in unconditional logistic models. The
breast cancer expression of estrogen and progesterone receptors was
Fig. 1. Associations between the concentrations of persistent organic pollutants in adipose tissue and the presence of large tumor size (≥2 cm vs<2 cm). The forest
plots represent the odds ratios and 95% confidence intervals estimated through unconditional logistic regression. Model 1 - Crude model; Model 2 – adjusted for age,
body mass index and familial history of breast cancer.
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further considered in the stratification analysis but was limited to the
positive phenotypes due to the low number of receptor-negative tu-
mors.
Serum biomarkers were considered as surrogates of peritumoral AT
biomarkers and were considered only in the global models to evaluate
the coherence of estimates with AT models. For that reason, these proxy
circulating markers were not considered in the stratification analysis
and were relegated to secondary outcomes in the results section. Since
lipid normalized concentrations of POPs in serum may lead to biased
estimates when serum lipids may fall in the causal pathway between the
exposures and the outcomes, a systematic comparison of different ap-
proaches was conducted (Cano-Sancho et al., 2018; O'Brien et al.,
2016). Hence, we considered the Model WW, that uses serum con-
centrations expressed on a wet basis (pg or ng/mL); the Model WWA,
that uses serum concentrations expressed on a wet basis (pg or ng/mL)
and the TSA included as a covariate in the regression model; Model LW,
that uses serum concentrations on a lipid basis (pg or ng/g lipids);
Model LWA, that uses serum concentrations on a lipid basis (pg or ng/
g lipids) and the TSA also included as a covariate in the regression
model. We further tested the associations between metastasis and the
ratio of concentrations between both matrices, serum and adipose
tissue (Rser:AT), as a multi-compartment biomarker (Ploteau et al.,
2016). In equilibrated states, the concentrations of both compartments
expressed in lipid weight should be equivalent, and the Rser:AT should be
close to 1, conversely, altered states would be reflected by esti-
mates> 1.
Mixtures of parent chemicals were generated by sum of concentra-
tions and/or sum of 2005 World Health Organization dioxin-like toxic
equivalents (WHO-TEQ). A threshold for the p-value < 0.05 was used
to define associations as statistically significant. Considering the hy-
pothesis-driven design of this study, the relatively small number of
multiple tests conducted and the high correlation among variables
tested, we opted not to correct for the multiple comparisons which
minimizes the risk of inflating the type 2 errors (Rothman, 1990). All
the statistical analyses were performed using R (v.3.3.1.) software.
3. Results
3.1. Demographic characteristics
A summary of the study population's characteristics is presented in
Table 1 and Table S2 (participants with and without metastases). Both
datasets reflected the homogeneity of the groups. The median age of
participants ranged from 58 to 67 years. A majority of women had
undergone menopause (71–85%). The most frequent histological sub-
type in both groups was infiltrating ductal carcinoma. There was no
difference in the expression of ER, PR and HER2. As expected, the
number of lymph nodes, the frequency of larger tumors and the Ki-67
proliferation index> 20%, were higher among patients with metastatic
cancer. For several participants, the volume of serum or the amount of
adipose tissue was insufficient to complete the chemical analyses and
vice versa. Therefore, the serum dataset contained the results derived
from 40 participants with metastatic cancer and 47 with non-metastatic
cancer, different than the 38 participants with metastatic cancer and 53
with non-metastatic cancer recorded in the AT dataset.
3.2. Distribution of persistent organic pollutants
The distributions of POPs in AT and serum are summarized in
Table 2 and in Tables S3 and S4. Chemicals with detection rates lower
than 75% (i.e. PBB52, PBB101, β-HBCD, γ-HBCD in AT and serum and
α-HBCD in addition in serum) were excluded from the statistical ana-
lysis. The POPs distribution was not statistically different between both
groups.
After normalization by lipid content, the concentrations in AT and
serum were highly correlated for most chemicals (Fig. S1A–B).
However, most flame retardants in AT exhibited lower correlations with
their circulating levels, although there were several exceptions (Fig.
S1C). The correlation structures between chemicals appeared to be al-
most identical between metastatic and non-metastatic cancers in both
AT and serum (Figs. S2–3).
Table 1
Population characteristics (Median and interquartile range (IQR) or counts and
frequency percentages) from the adipose tissue dataset for individuals with
breast cancer with metastasis or without metastasis. The distributions between
groups have been compared with Mann–Whitney U test for continuous data and
Fisher's exact test for categorical data.
Metastatic
N=38
Non-metastatic
N=53
p-Value
Age (years) 59.8
(52.9–74.3)
64.0 (51.0–73.0) 0.99
BMI (kg/m2) 24.0
(21.4–27.8)
24.0 (21.0–27.0) 0.63
Parity (number of infants) 0.94
0 8 (21%) 13 (25%)
1 8 (21%) 13 (25%)
2 12 (32%) 15 (28%)
≥3 10 (26%) 12 (22%)
Breastfeeding 18 (47%) 25 (47%) 1.00
Missing 1 3
Menopause 27 (71%) 38 (72%) 1.00
Missing 1 0
Hormonal contraception 9 (24%) 11 (21%) 0.80
Missing 2 1
Professional category 0.27
White collar 17 (45%) 30 (57%)
Blue collar 2 (5%) 2 (4%)
Pink collar 17 (45%) 15 (28%)
Un-employed/students 1 (3%) 5 (10%)
Living area 0.17
Rural 5 (13%) 2 (4%)
Urban 33 (87%) 50 (94%)
Mixt 0 (0%) 1 (2%)
First-hand smoking 8 (21%) 9 (17%) 0.60
Missing 1 0
Second-hand smoking 4 (11%) 10 (19%) 0.38
Missing 1 0
Personal history of cancer 2 (5%) 5 (9%) 0.69
Family history of breast cancer 8 (21%) 14 (26%) 0.62
Missing 0 1
Histopathological examinations
Triple negative 4 (11%) 6 (11%) 1.00
Estrogen receptor positive 33 (87%) 44 (83%) 0.77
Progesterone receptor positive 27 (71%) 36 (68%) 0.82
Tumor size 0.001
0.1–2 cm 12 (32%) 31 (58%)
3.1–5 cm 20 (53%) 22 (42%)
> 5 cm 6 (16%) 0 (0%)
Affected lymph nodes < 0.0001
≤ 3 nodes 26 (68%) 0 (0%)
4–9 nodes 9 (24%) 0 (0%)
≥10 nodes 3 (8%) 0 (0%)
No applicable 0 (0%) 53 (100%)
Grade histology 0.68
1 5 (13%) 10 (19%)
2 21 (55%) 25 (47%)
3 12 (32%) 18 (34%)
Histological classification 0.89
Infiltrating ductal
carcinoma
31 (82%) 40 (75%)
Infiltrating lobular
carcinoma
6 (16%) 9 (17%)
Papillary carcinoma 0 (0%) 2 (4%)
Mucinous (colloid)
carcinoma
1 (3%) 1 (2%)
Apocrin carcinoma 0 (0%) 1 (2%)
HER2 Positive 2 (5%) 6 (11%) 0.46
Ki-67 0.03
< 20% 12 (32%) 29 (55%)
> 20% 26 (68%) 24 (45%)
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3.3. Associations between POPs and risk of breast cancer metastasis
The summary of adjusted ORs (95% CI) for the major chemical
groups is presented in Table 3 whereas the detailed graphical summary
of ORs and 95% CIs for the different models and chemicals is plotted in
Fig. S4. Overall, the results from the different models using AT bio-
markers did not show any significant association between POPs and the
risk of metastasis. The ORs and respective 95% CI were uniformly
distributed around the null. The Seveso dioxin 2.3.7.8-TCDD exhibited
substantially higher adjusted ORs (1.72 (0.56–6.03)) than the rest of
PCDDs or their sum (0.67 (0.28–1.54)) (model 4, Fig. S4, Table 3).
Moreover, when these analyses were restricted to a sub-group with a
high BMI (≥25 kg/m2), the ORs were larger and the risk of BC
metastasis was significantly larger for 2.3.7.8-TCDD (aOR 4.48
(1.32–20.71)). Other chemicals such as PBDE 153 (aOR 2.27
(1.06–6.00)), 1.2.3.4.7.8 HxCDD or PCB114 also displayed higher ORs
(> 2) with p values below 0.1 (Table 4). The results for the subgroup
with a normal BMI (< 25 kg/m2) displayed null associations for all
chemicals with ORs shifting below one for a large list of chemicals in-
cluding 2.3.7.8-TCDD, the WHO-TEQ Sum of PCDD/F or the non-co-
planar PCBs, which supports the concept that BMI modifies effects.
The stratification analyses taking into account only the sub-groups
of individuals with breast cancer and the expression of estrogen and
progesterone receptors are summarized in the Table S5. The results
from both sub-groups showed very similar association patterns, with a
global modification of the ORs towards the null or below. Remarkably,
Table 2
Summary of the (median (interquartile range)) of persistent organic pollutants measured in adipose tissue from individuals with metastatic and non-metastatic breast
cancer. The groups were compared with the Mann-Whitney U test.
Chemicalsa Units Metastatic (n= 38) Non-metastatic (n= 53) p-Value
2.3.7.8-TCDD pg/g l.w. 1.4 (1.1–1.8) 1.3 (0.9–2.0) 0.70
1.2.3.7.8-PeCDD pg/g l.w. 4.6 (3.7–5.9) 4.5 (3.6–6.6) 0.86
1.2.3.4.7.8-HxCDD pg/g l.w. 2.3 (1.8–2.8) 2.2 (1.4–3.7) 0.72
1.2.3.6.7.8-HxCDD pg/g l.w. 14.7 (11.9–19.8) 15.4 (9.2–24.4) 0.62
1.2.3.7.8.9-HxCDD pg/g l.w. 1.6 (1.1–2.3) 1.5 (1.1–2.8) 0.73
1.2.3.4.6.7.8-HpCDD pg/g l.w. 12.6 (8.1–19.8) 12.9 (6.7–23.8) 0.61
OCDD pg/g l.w. 91.3 (60.4–123.3) 102.7 (71.8–162.1) 0.18
Sum PCDDs pg/g l.w. 126.7 (92.4–180.5) 139.8 (96.9–235.1) 0.32
2.3.7.8-TCDF pg/g l.w. 0.4 (0.3–0.5) 0.4 (0.3–0.6) 0.86
1.2.3.7.8-PeCDF pg/g l.w. 0.2 (0.1–0.3) 0.2 (0.1–0.3) 0.64
2.3.4.7.8-PeCDF pg/g l.w. 12.0 (8.7–14.9) 11.2 (8.6–19.3) 0.67
1.2.3.4.7.8-HxCDF pg/g l.w. 2.0 (1.6–2.6) 2.2 (1.7–3.4) 0.41
1.2.3.6.7.8-HxCDF pg/g l.w. 2.4 (1.8–2.9) 2.5 (1.9–3.7) 0.46
1.2.3.7.8.9-HxCDF pg/g l.w. 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.61
2.3.4.6.7.8- HxCDF pg/g l.w. 0.8 (0.6–1.0) 0.8 (0.5–1.1) 0.96
1.2.3.4.6.7.8-HpCDF pg/g l.w. 1.2 (0.8–1.6) 1.3 (1.0–1.8) 0.24
1.2.3.4.7.8.9-HpCDF pg/g l.w. 0.1 (0.1–0.2) 0.1 (0.1–0.1) 0.83
OCDF pg/g l.w. 0.3 (0.2–0.6) 0.3 (0.2–0.4) 0.46
Sum PCDFs pg/g l.w. 19.3 (16.4–26.2) 19.6 (14.9–29.8) 0.62
WHO-TEQ2005 PCDD/F TEF2005/g l.w. 11.8 (10.3–15.1) 11.6 (9.4–17.8) 0.81
PCB 77 pg/g l.w. 4.3 (2.8–7.8) 6.7 (3.4–11.9) 0.16
PCB 81 pg/g l.w. 2.1 (1.1–3.0) 2.4 (1.3–4.7) 0.14
PCB 126 pg/g l.w. 61.0 (42.8–81.5) 62.5 (40.7–103.6) 0.77
PCB 169 pg/g l.w. 79.0 (56.0–117.3) 84.0 (53.4–134.7) 0.94
Sum Copl. PCBs pg/g l.w. 147.9 (106.9–217.9) 180.8 (103.3–241.4) 0.58
PCB 105 pg/g l.w. 4379.0 (2641.4–6129.3) 5247.4 (2473.8–11,189.3) 0.24
PCB 114 pg/g l.w. 1941.0 (1223.7–3227.5) 2329.2 (857.6–3397.8) 0.75
PCB 118 pg/g l.w. 20,010.1 (13,746.8–28,123.0) 24,288.5 (14,501.8–47,869.5) 0.37
PCB 123 pg/g l.w. 183.2 (132.3–373.8) 268.2 (140.5–573.7) 0.40
PCB 156 pg/g l.w. 21,177.7 (12,023.5–31,398.0) 20,850.0 (11,068.6–37,322.1) 0.88
PCB 157 pg/g l.w. 4496.6 (2325.4–6408.0) 4030.0 (1927.7–7644.8) 0.77
PCB 167 pg/g l.w. 4466.9 (2787.1–7229.4) 4314.9 (2698.6–7531.7) 0.91
PCB 189 pg/g l.w. 2801.2 (1811.9–4222.3) 2871.9 (1639.3–4313.4) 0.81
Sum Non Cop. PCBs pg/g l.w. 59,011.5 (39,991.2–93,646.3) 62,660.2 (36,089.7–115,909.2) 0.59
WHO-TEQ2005 PCB s TEF2005/g l.w. 10.7 (7.2–15.7) 11.5 (7.8–18.0) 0.57
TOTAL WHO-TEQ2005 TEF2005/g l.w. 22.5 (16.9–30.8) 24.1 (16.1–35.2) 0.71
PCB 28 ng/g l.w. 1.7 (0.9–2.4) 1.9 (1.0–3.0) 0.62
PCB 52 ng/g l.w. 0.3 (0.2–0.6) 0.4 (0.2–0.7) 0.26
PCB 101 ng/g l.w. 0.7 (0.5–1.4) 1.0 (0.5–1.9) 0.17
PCB 138 ng/g l.w. 71.9 (52.9–100.9) 72.3 (40.5–124.7) 0.89
PCB 153 ng/g l.w. 193.0 (131.1–253.3) 166.2 (117.6–283.4) 0.82
PCB 180 ng/g l.w. 168.4 (120.5–270.1) 156.6 (106.1–277.4) 0.63
Sum 6 non dioxin-like PCB ng/g l.w. 438.6 (291.2–621.3) 391.5 (261.6–710.6) 0.78
PBDE 28 ng/g l.w. 0.021 (0.010–0.036) 0.025 (0.015–0.045) 0.18
PBDE 47 ng/g l.w. 0.238 (0.138–0.491) 0.361 (0.162–0.646) 0.23
PBDE 99 ng/g l.w. 0.067 (0.037–0.112) 0.079 (0.039–0.166) 0.42
PBDE 100 ng/g l.w. 0.123 (0.056–0.207) 0.119 (0.071–0.241) 0.61
PBDE 153 ng/g l.w. 1.440 (1.054–1.899) 1.436 (1.013–1.915) 0.98
PBDE 154 ng/g l.w. 0.025 (0.015–0.034) 0.024 (0.017–0.048) 0.66
PBDE 183 ng/g l.w. 0.122 (0.083–0.201) 0.142 (0.092–0.188) 0.68
PBDE 209 ng/g l.w. 1.761 (1.275–2.199) 1.454 (1.088–1.941) 0.27
Sum penta and hepta BDE ng/g l.w. 2.296 (1.447–3.039) 2.288 (1.697–3.175) 0.66
Sum penta, hepta and deca BDE ng/g l.w. 4.381 (3.484–5.537) 3.981 (3.016–5.299) 0.45
PBB 153 ng/g l.w. 0.609 (0.440–0.842) 0.640 (0.488–0.883) 0.47
α-HBCD ng/g l.w. 1.020 (0.600–1.769) 1.615 (0.965–1.952) 0.18
a Note: PBB 52, PBB 101, β-HBCD and γ-HBCD presented<75% of detected samples and excluded from the statistical analysis.
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the negative associations with PCB 101, PBDE28, PBDE 47 and PBDE99
became statistically significant for both groups (p < 0.01). The
number of participants with a negative expression of the estrogen re-
ceptor (n=14) and triple negative breast cancer (n= 10) were too
small to allow the computation of regression models, but the metastatic
group exhibited, in general, larger concentrations of all POPs with
statistically significant differences (Mann-Whitney U test, summary in
Table S6) for 1.2.3.4.6.7.8-HpCDF (p < 0.01) and PCBs 101, 138, 153,
167 and the sum Ndl-PCBs and the sum of 8 PBDEs (p < 0.05).
With respect to serum biomarkers, the ORs and 95% CIs also were
distributed around the null for most chemicals with minor effects for
confounding variables (Fig. S5). Also, the systematic comparisons of
serum models did not reveal a major effect of TSL on the risk estimates
for any of the models for most chemicals (See details in Fig. S6). These
results also suggested a lack of consistency among the risk models using
AT biomarkers with the serum biomarkers for some chemicals where
the associations shifted in the opposite direction (e.g. 2.3.7.8-TCDD or
OCDF). To further explore the potential implications of the chemical
dynamics among both compartments on the risk estimates, we included
the ratio among compartments RSer:AT as an independent variable in the
risk models. The results from the logistic regression using RSer:AT are
summarized in the Fig. S7. In general, the ORs for the ratios were close
to the null, exhibiting similar trends to those results reported for AT and
serum biomarkers; that is, the RSer:AT of Seveso dioxin, 2.3.7.8-TCDD
consistently associated with the risk of metastasis (1.72 (1.02–3.09))
(Table 5).
4. Discussion
Given the role of the cellular microenvironment on BC metastasis,
we have explored, for the first time, the associations between the in-
ternal dose of a large panel of POPs and the risk of BC metastasis. Our
study shows the widespread presence of low amounts of POPs in human
tissues despite the fact that most of the chemicals were banned many
years ago. The concentrations of these chemicals are similar to those
previously reported in France which supports a background exposure in
our study individuals comparable with that of the general population
(Ploteau et al., 2017).
To date, only a few studies have explored the associations between a
large panel of POPs and BC metastasis. For example, positive associa-
tions have been found between the internal concentrations of OCP and
tumor size (Demers et al., 2000; Høyer et al., 2001). Women with
higher concentrations of PCBs (particularly PCB118) were found to
have a higher risk of BC recurrence, (Muscat et al., 2003). PCB 118 was
one of the PCBs that we found to be associated with tumor size. Our
results suggest that 2.3.7.8-TCDD may be a risk factor for BC aggres-
siveness and a predictor of poor prognosis, especially among over-
weight women. Obesity is recognized as a factor for poor prognosis in
BC due to aggressive features of the tumor and resistance to treatment
(Barba et al., 2016; Jiralerspong and Goodwin, 2016). In previous
work, we showed that AT releases POPs chronically and slowly (Kim
et al., 2011). This internal release may be responsible for the chronic
toxicity associated with POPs exposure (Joffin et al., 2018). Moreover,
we have shown that POPs promote an epithelial-to-mesenchymal
transition which is suspected to promote the formation of metastatic
cells (Bui et al., 2009; Pierre et al., 2014). Therefore, in this study, we
evaluated the potential involvement of adiposity through stratification
of a sub-group of the study population with high BMI. The subgroup
analysis revealed a different pattern of associations which enlarged the
ORs (95% CI) for 2.3.7.8-TCDD, the most toxic of dioxins.
TCDD (and several PCBs, such as PCB 77 and 169) activate the Aryl
hydrocarbon Receptor (AhR) signalling pathway. The AhR regulates the
expression of xenobiotic metabolism enzymes (such as cytochromes
P450) upon exposure to different types of hydrocarbons including di-
oxins or various PCBs. Recently, other gene targets have been identified
which include transcriptional regulators of the EMT such as Slug and
Snail (Pierre et al., 2014). As a consequence, the induction of Slug or
Snail by TCDD through the activation of the AhR signalling pathway
down-regulates the epithelial marker, E-Cadherin. This facilitates the
migration of tumor cells (Diry et al., 2006). The AhR also regulates non-
genomic pathways (Src and Focal Adhesion Kinase) which are im-
portant for the stability of focal adhesion sites (Tomkiewicz et al.,
2013). Thus, the activation of the AhR signalling pathway by xeno-
biotics has been suspected to play a potential role in tumor progression.
This suspicion is supported by the identification of TCDD as a potential
biomarker of metastasis. In addition to TCDD, we also have found that
two coplanar PCBs (77&169) in AT are positively associated with the
risk of lymph node metastasis and tumor size. These two PCBs are two
DLCs. The toxic equivalent factor (TEF) of PCB 169 is 0.01, one of the
highest among all coplanar PCBs. The identification of these two acti-
vators of the AhR signalling pathway as potential biomarkers of tumor
size and risk of lymph node metastasis also is consistent with the pre-
vious suspicion.
Several hypotheses can be formulated to explain the contribution of
the adipocytic microenvironment to tumor aggressiveness which in-
clude the secretion of pro-migratory cytokines and chemokines or pro-
inflammatory molecules the expression of which could be potentiated
by the presence of AhR ligands (Diedrich et al., 2015). Emerging evi-
dence also has shown that POPs may contribute to a dysfunctional
adipocyte phenotype. This phenotype is characterized by an increased
production of pro-inflammatory cytokines, oxidative stress and lipolytic
rates which favor the local over-release of stored chemicals and pro-
tumoral molecules by the peritumoral adipocytes (Artacho-Cordón
et al., 2016; Howell and Mangum, 2011; Pestana et al., 2017; Ruzzin
et al., 2010). These findings suggest that some chemicals may sy-
nergistically contribute to the metastatic risk through peritumoral
adipocyte dysfunction in addition to the direct effects on breast cancer
cells. Such a hypothesis would help to elucidate the gaps between
Table 3
Summary estimates for the associations between the sums of concentrations of PCDDs, PCDFs, PCBs, PBDEs and PBB153 in adipose tissue and the risk of breast cancer
metastasis represented with the odds ratios and 95% confidence intervals estimated from unconditional logistic regression (N=91, 38 cases with metastatic cancer
and 53 with non-metastatic cancer). The model was adjusted for age, smoking, body mass index, menopause and familial history of breast cancer. Abbreviations:
WHO-TEQ, World Health Organization Dioxin-like Toxic Equivalents. NA: not applicable because the low detection rates. Ndl, non-dioxin like.
Chemical groups Adipose tissue adjusted OR (95% CI) p value Serum adjusted OR (95% CI) p value
Sum PCDDs 0.67 (0.28–1.54) 0.36 0.81 (0.41–1.59) 0.55
Sum PCDFs 0.70 (0.20–2.45) 0.57 0.93 (0.26–3.31) 0.91
Sum PCDD/Fs WHO-TEQ 0.90 (0.28–3.02) 0.86 0.96 (0.34–2.70) 0.93
Sum Coplanar PCBs 0.85 (0.33–2.19) 0.74 1.15 (0.46–2.96) 0.77
Sum Non-Coplanar PCBs 0.93 (0.38–2.25) 0.86 1.11 (0.57–2.20) 0.75
Sum PCBs WHO-TEQ 0.83 (0.33–2.08) 0.70 1.15 (0.52–2.59) 0.73
Sum Ndl-PCB 1.18 (0.48–2.99) 0.72 1.23 (0.58–2.67) 0.60
Sum PBDEs 1.32 (0.61–3.02) 0.49 1.73 (0.65–4.78) 0.27
PBB 153 0.80 (0.33–1.92) 0.62 1.23 (0.44–3.70) 0.70
α-HBCD 1.02 (0.57–1.80) 0.93 NA NA
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exposure to POPs, adiposity and breast cancer (Blücher and Stadler,
2017).
Furthermore, the OR (95% CI) was also enlarged in the sub-group of
patients with> 3 metastatic lymph nodes which suggests an associa-
tion between the metastatic stage and TCDD concentration. Finally,
larger tumor size was associated with the presence of higher con-
centrations of TCDD and some PCBs for which statistically significant
associations were observed after confounding adjustment. The statisti-
cally significant negative associations found for the ER+ and PR+ sub-
groups suggest receptor status can modify effects. They also highlight
the need for studies with larger numbers of individuals with breast
cancers with negative expression which are already acknowledged to be
the most aggressive forms with the worst prognosis.
Although AT is accepted as the gold standard matrix for the eva-
luation of the internal dose of POPs, little is known about the dynamics
of lipophilic pollutants in the breast microenvironment. In the current
study, we made a substantial analytical effort to decipher the complex
relationships between the concentrations of chemicals in two major
compartments, AT and serum. Although the results showed a strong
correlation of chemicals between both compartments, the application of
such biomarkers in the regression models resulted in divergent risk
estimates. Overall, these results suggest that the use of serum
Table 4
Associations between concentrations of persistent organic pollutants in adipose tissue and metastatic breast cancer for the sub-population group with BMI ≥25 kg/
m2 (n=44) and BMI< 25 kg/m2 (n= 47). The models were adjusted for age, smoking, body mass index, menopause and familial history of breast cancer.
Chemical BMI≥ 25 kg/m2 BMI < 25 kg/m2
OR 95% CI p-Value OR 95% CI p-Value
2.3.7.8_TCDD 4.48 (1.32–20.71) 0.03 0.90 (0.38–2.5) 0.83
1.2.3.7.8_PeCDD 2.07 (0.78–6.45) 0.17 0.66 (0.28–1.57) 0.33
1.2.3.4.7.8_HxCDD 2.92 (0.94–11.31) 0.09 1.07 (0.45–2.58) 0.88
1.2.3.6.7.8_HxCDD 1.70 (0.67–5.13) 0.29 0.73 (0.31–1.72) 0.45
1.2.3.7.8.9_HxCDD 0.97 (0.40–2.29) 0.95 0.87 (0.4–1.86) 0.71
1.2.3.4.6.7.8_HpCDD 0.89 (0.39–2.00) 0.77 0.71 (0.3–1.62) 0.42
OCDD 0.75 (0.33–1.56) 0.45 0.70 (0.33–1.42) 0.33
Sum_PCDDs 0.79 (0.35–1.73) 0.56 0.74 (0.34–1.53) 0.42
2.3.7.8_TCDF 0.83 (0.40–1.64) 0.59 0.89 (0.46–1.66) 0.71
1.2.3.7.8_PeCDF 0.92 (0.45–1.83) 0.80 0.94 (0.5–1.75) 0.85
2.3.4.7.8_PeCDF 2.09 (0.72–6.92) 0.19 0.60 (0.26–1.36) 0.22
1.2.3.4.7.8_HxCDF 1.01 (0.37–2.81) 0.99 0.72 (0.34–1.52) 0.39
1.2.3.6.7.8_HxCDF 1.36 (0.50–3.91) 0.55 0.65 (0.3–1.37) 0.26
1.2.3.7.8.9_HxCDF 1.33 (0.61–2.91) 0.45 1.15 (0.6–2.31) 0.68
2.3.4.6.7.8_HxCDF 1.09 (0.50–2.47) 0.83 1.15 (0.6–2.22) 0.68
1.2.3.4.6.7.8_HpCDF 0.90 (0.39–1.86) 0.79 0.96 (0.49–1.89) 0.90
1.2.3.4.7.8.9_HpCDF 0.83 (0.35–1.81) 0.65 1.29 (0.68–2.66) 0.45
OCDF 1.66 (0.80–3.92) 0.19 1.28 (0.65–2.76) 0.49
Sum PCDFs 1.48 (0.52–4.46) 0.46 0.71 (0.32–1.57) 0.39
WHO-TEQ Sum PCDD/F 2.22 (0.75–7.69) 0.17 0.70 (0.29–1.7) 0.40
PCB77 0.85 (0.36–1.88) 0.69 0.76 (0.37–1.49) 0.43
PCB81 0.87 (0.40–1.77) 0.70 0.62 (0.28–1.25) 0.20
PCB126 1.17 (0.51–2.74) 0.70 0.87 (0.39–1.9) 0.72
PCB169 2.84 (0.85–12.62) 0.12 0.82 (0.36–1.95) 0.64
Sum Coplanar PCBs 1.44 (0.53–4.24) 0.48 0.80 (0.35–1.83) 0.59
PCB105 1.06 (0.45–2.48) 0.90 0.70 (0.32–1.45) 0.35
PCB114 2.70 (0.94–9.31) 0.08 0.67 (0.29–1.53) 0.33
PCB118 1.39 (0.55–3.64) 0.49 0.67 (0.3–1.45) 0.31
PCB123 1.33 (0.55–3.29) 0.52 0.67 (0.3–1.46) 0.32
PCB156 2.95 (0.89–12.76) 0.10 0.84 (0.37–2) 0.68
PCB157 2.09 (0.80–6.46) 0.16 0.93 (0.4–2.45) 0.88
PCB167 3.61 (0.98–17.00) 0.07 0.70 (0.3–1.62) 0.40
PCB189 1.86 (0.69–5.96) 0.25 1.11 (0.48–2.74) 0.80
Sum Non-Coplanar PCBs 1.94 (0.67–6.33) 0.23 0.71 (0.31–1.64) 0.42
WHO-TEQ PCB 1.33 (0.51–3.59) 0.55 0.79 (0.35–1.78) 0.56
TOTAL WHO-TEQ 1.80 (0.61–5.95) 0.30 0.74 (0.31–1.8) 0.49
PCB28 1.13 (0.56–2.31) 0.72 0.86 (0.41–1.73) 0.68
PCB52 0.69 (0.29–1.41) 0.34 0.66 (0.31–1.33) 0.26
PCB101 0.67 (0.28–1.43) 0.33 0.74 (0.36–1.46) 0.38
PCB138 1.86 (0.73–5.52) 0.22 0.89 (0.44–1.76) 0.72
PCB153 2.01 (0.74–6.41) 0.20 0.96 (0.46–2.05) 0.92
PCB180 1.65 (0.66–4.73) 0.31 1.22 (0.55–2.94) 0.64
Sum 6 non dioxin-like PCB 1.92 (0.70–6.06) 0.22 0.99 (0.47–2.24) 0.99
Sum 7 non dioxin-like PCB 1.98 (0.71–6.34) 0.21 0.97 (0.46–2.19) 0.95
PBDE28 0.68 (0.33–1.33) 0.26 0.70 (0.35–1.29) 0.27
PBDE47 0.64 (0.29–1.31) 0.24 0.88 (0.46–1.64) 0.67
PBDE99 0.71 (0.33–1.47) 0.37 0.87 (0.44–1.66) 0.67
PBDE100 0.90 (0.43–1.89) 0.77 0.89 (0.46–1.68) 0.71
PBDE153 2.27 (1.06–6.00) 0.06 0.63 (0.27–1.26) 0.22
PBDE154 0.68 (0.31–1.39) 0.29 1.02 (0.54–1.94) 0.96
PBDE183 0.78 (0.38–1.54) 0.48 0.96 (0.49–1.88) 0.90
PBDE209 1.17 (0.57–2.43) 0.67 1.07 (0.57–2.08) 0.82
Sum 7 PBDE 1.19 (0.59–2.48) 0.63 0.73 (0.35–1.39) 0.35
Sum 8 PBDE 1.14 (0.56–2.37) 0.72 1.14 (0.6–2.23) 0.68
PBB153 1.40 (0.64–3.50) 0.42 0.58 (0.28–1.13) 0.12
α-HBCD 1.55 (0.60–4.67) 0.39 0.88 (0.37–1.99) 0.76
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biomarkers may result in inconsistent findings if used as surrogate
biomarkers in peritumoral AT. These results are consistent not only
with those of our previous studies in the field of endometriosis where
serum biomarkers exhibited substantial disagreement with the esti-
mates using AT biomarkers (Cano-Sancho et al., 2018) but also with
growing evidence about the complexity of use and interpretation of
circulating biomarkers (O'Brien et al., 2016). Future studies need take
into account the use longitudinal markers of exposure that would ap-
proximate lifetime trajectories either by optimally using multiple
sample time-points or by reconstruction of exposure trajectories
through PBPK modeling (Verner et al., 2011).
The results from this study should be considered with caution due to
some methodological limitations. For instance, this exploratory study
has a limited sample size and was conducted within a clinical setting to
deliver definitive inferential conclusions at a population level. For that
reason, large population-based studies with greater statistical power
and a lower risk of selection bias are necessary to confirm the findings.
Furthermore, we purposely opted not to adjust for the multiple tests
performed in this exploratory analysis because the hypothesis-based
approach, of the high correlation between variables and to avoid the
consequential inflation of type 2 errors (Rothman, 1990). For that
reason, the results should be interpreted with caution in the light of
potential type 1 errors which result in some associations due to chance.
Another limitation is the measurement error derived from using proxy
biomarkers instead of target tissue before the onset of the metastasis.
The design of the present study may not rule out some potential reverse
Table 5
Summary of the levels (median (interquartile range)) of persistent organic pollutants measured in adipose tissue from the population dichotomized on the basis of the
median of tumor size distribution. The groups were compared with the Mann-Whitney test.
Units Small size <2 cm
N=43
Large size ≥2 cm
N=48
p-Value
2.3.7.8-TCDD pg/g l.w. 1.2 (0.9–1.5) 1.6 (1.1–2.3) 0.003
1.2.3.7.8-PeCDD pg/g l.w. 4.4 (3.4–5.7) 5.0 (3.7–6.7) 0.25
1.2.3.4.7.8-HxCDD pg/g l.w. 1.9 (1.3–2.9) 2.6 (1.9–4.0) 0.017
1.2.3.6.7.8-HxCDD pg/g l.w. 14.3 (9.1–19.7) 15.8 (11.9–25.6) 0.24
1.2.3.7.8.9-HxCDD pg/g l.w. 1.4 (1.0–2.0) 1.7 (1.1–2.7) 0.15
1.2.3.4.6.7.8-HpCDD pg/g l.w. 11.1 (6.2–16.9) 14.5 (8.6–24.0) 0.098
OCDD pg/g l.w. 89.4 (62.6–132.8) 98.6 (72.1–159.3) 0.37
Sum PCDDs pg/g l.w. 126.2 (92.8–186.8) 142.7 (102.5–217.4) 0.21
2.3.7.8-TCDF pg/g l.w. 0.3 (0.2–0.5) 0.4 (0.3–0.6) 0.17
1.2.3.7.8-PeCDF pg/g l.w. 0.2 (0.1–0.2) 0.2 (0.1–0.3) 0.41
2.3.4.7.8-PeCDF pg/g l.w. 10.9 (7.9–15.7) 12.2 (9.3–19.3) 0.15
1.2.3.4.7.8-HxCDF pg/g l.w. 2.0 (1.5–2.6) 2.3 (1.8–3.4) 0.063
1.2.3.6.7.8-HxCDF pg/g l.w. 2.1 (1.7–3.0) 2.6 (1.9–3.9) 0.096
1.2.3.7.8.9-HxCDF pg/g l.w. 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.26
2.3.4.6.7.8- HxCDF pg/g l.w. 0.7 (0.5–0.9) 0.8 (0.6–1.1) 0.28
1.2.3.4.6.7.8-HpCDF pg/g l.w. 1.3 (0.8–1.6) 1.2 (0.9–1.6) 0.94
1.2.3.4.7.8.9-HpCDF pg/g l.w. 0.1 (0.1–0.2) 0.1 (0.1–0.1) 0.52
OCDF pg/g l.w. 0.2 (0.2–0.4) 0.3 (0.2–0.6) 0.16
Sum PCDFs pg/g l.w. 18.1 (14.3–29.2) 21.7 (16.8–29.8) 0.11
Sum WHO-TEQ PCDD/F TEF2005/g l.w. 11.3 (8.6–15.8) 12.6 (10.3–18.4) 0.15
PCB 77 pg/g l.w. 5.9 (3.2–11.9) 5.3 (3.3–10.9) 1.00
PCB 81 pg/g l.w. 1.9 (0.9–3.8) 2.5 (1.5–3.9) 0.11
PCB 126 pg/g l.w. 52.0 (34.3–80.9) 68.2 (49.9–112.5) 0.020
PCB 169 pg/g l.w. 79.9 (47.3–125.0) 85.9 (59.4–140.1) 0.22
Sum Coplanar PCBs pg/g l.w. 137.1 (95.6–202.9) 180.6 (115.6–279.9) 0.064
PCB 105 pg/g l.w. 3397.2 (2315.0–6149.0) 5020.7 (3321.5–10,981.6) 0.044
PCB 114 pg/g l.w. 1633.8 (811.1–2883.6) 2565.9 (1468.1–4056.5) 0.051
PCB 118 pg/g l.w. 18,165.3 (11,329.7–29,421.4) 25,612.6 (15,978.2–47,962.2) 0.027
PCB 123 pg/g l.w. 179.6 (94.5–288.0) 301.3 (150.7–576.7) 0.009
PCB 156 pg/g l.w. 19,468.7 (9259.6–30,824.5) 23,091.2 (13,586.1–37,411.0) 0.27
PCB 157 pg/g l.w. 3602.2 (1868.1–6655.3) 4584.9 (2438.8–7011.3) 0.34
PCB 167 pg/g l.w. 3814.3 (2330.8–5996.2) 5220.7 (3174.9–7808.8) 0.056
PCB 189 pg/g l.w. 2726.2 (1616.2–4279.3) 3020.1 (1723.9–4290.8) 0.62
Sum Non Coplanar PCBs pg/g l.w. 56,735.1 (33,999.6–85,933.3) 72,402.4 (46,204.6–115,654.6) 0.081
WHO-TEQ dl-PCB TEF2005/g l.w. 10.2 (6.2–13.6) 12.4 (8.1–20.6) 0.039
TOTAL WHO-TEQ TEF2005/g l.w. 21.7 (15.8–30.0) 25.7 (18.7–38.1) 0.048
PCB 28 ng/g l.w. 1.1 (0.8–2.3) 2.2 (1.2–3.5) 0.007
PCB 52 ng/g l.w. 0.3 (0.2–0.6) 0.4 (0.3–0.7) 0.056
PCB 101 ng/g l.w. 0.7 (0.5–1.5) 1.0 (0.6–2.0) 0.13
PCB 138 ng/g l.w. 67.1 (39.9–101.5) 81.0 (56.1–125.5) 0.15
PCB 153 ng/g l.w. 163.6 (119.8–280.4) 201.9 (126.9–289.1) 0.27
PCB 180 ng/g l.w. 160.2 (104.0–277.1) 164.9 (114.0–246.8) 0.74
Sum 6 ndl-PCB ng/g l.w. 388.5 (275.9–683.3) 474.2 (280.4–717.4) 0.32
PBDE 28 ng/g l.w. 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.86
PBDE 47 ng/g l.w. 0.3 (0.1–0.7) 0.4 (0.2–0.5) 0.72
PBDE 99 ng/g l.w. 0.1 (0.0–0.2) 0.1 (0.0–0.1) 0.53
PBDE 100 ng/g l.w. 0.1 (0.1–0.3) 0.1 (0.1–0.2) 0.57
PBDE 153 ng/g l.w. 1.6 (1.0–2.1) 1.4 (1.0–1.8) 0.28
PBDE 154 ng/g l.w. 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.22
PBDE 183 ng/g l.w. 0.2 (0.1–0.2) 0.1 (0.1–0.2) 0.44
PBDE 209 ng/g l.w. 1.5 (1.3–2.2) 1.7 (0.9–2.1) 0.42
Sum 7 i PBDE ng/g l.w. 2.6 (1.7–3.6) 2.2 (1.5–2.8) 0.12
Sum 8 i PBDE ng/g l.w. 4.5 (3.7–5.7) 3.6 (3.0–5.3) 0.098
PBB 153 ng/g l.w. 0.6 (0.5–0.9) 0.6 (0.4–0.9) 0.44
α-HBCD ng/g l.w. 1.1 (0.6–2.0) 1.3 (0.9–2.0) 0.34
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causality as the main cause of the associations. In addition, in this first
analysis we have evaluated the associations for each chemical in-
dividually and only using sums of concentrations or bioactivities to
evaluate the effect of mixtures. Hence, we emphasize the need for
further research to evaluate the simultaneous effects of these chemicals
through more efficient statistical models. However, to date, there are
few statistical approaches that are available to efficiently identify the
combined associations of highly correlated chemicals reaching an op-
timal balance between bias and variance (Agier et al., 2016).
5. Conclusion
This exploratory study has investigated, for the first time, the as-
sociation between lymph node metastasis, the first step of BC dis-
semination, and the internal exposure to POPs. Although the study is
preliminary and consists of a limited sample size that precludes drawing
definitive conclusions, the results suggest that the internal exposure to
2.3.7.8-TCDD and some PCBs could be associated with the risk of ag-
gressive BC, in particular in obese patients and in patients with receptor
negative cancers, conditions which merit further research. Thus, larger
population-based longitudinal studies are necessary to confirm these
associations. In addition, fundamental research must develop to im-
prove our understanding at the mechanistic level of the effect of POPs
on metastatic cellular processes and potential cross-talk with peritu-
moral adipose tissue.
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